Pfizer (PFE) Q2 2026 Earnings Call Transcript
Pfizer (PFE) reported Q2 2026 revenue of $15.0B, up 1% operationally, and adjusted diluted EPS of $0.77. Non-COVID revenue grew 5%. The company raised revenue guidance to $60.5B-$62.5B, while cutting COVID guidance to about $4B. It cited cost discipline and productivity savings, and detailed product trends including Eliquis and Padcev growth.
How this was made
The 30-second read
Why it matters
Traders can update models based on the raised revenue guidance midpoint, the quantified COVID revenue reduction, and the stated $9.7B net cost savings through 2029 plus margin and R&D/SG&A trajectory.
Market read
A guidance raise with quantified product drivers and a large multi-year cost-savings program is likely to drive analyst estimate revisions and near-term sentiment for PFE.
What to watch
Leverage is expected to remain stable or rise modestly through the loss of exclusivity transition, which could constrain flexibility even with large net cost savings.
Background
This is Pfizer’s Q2 2026 earnings call transcript, covering financial results, revised revenue guidance, product performance, and multi-year cost savings and pipeline updates.
Ticker impact
Pfizer guided full-year revenue to $60.5B-$62.5B, raised the midpoint by $500M, and detailed non-COVID growth and COVID declines on the call.
Bias toward near-term upside as guidance is raised, partially offset by the large COVID revenue step-down and LOE-driven leverage outlook.
The article provides multiple concrete, company-specific datapoints: adjusted EPS $0.77, revenue guidance increase at the midpoint, and quantified product line changes (Eliquis, Padcev, Paxlovid, Comirnaty) plus $9.7B cost savings and leverage at 2.7x.
Market effects
Reinforces the large-cap pharma narrative of shifting growth from COVID to oncology and obesity, with cost discipline as a key driver.
Limited direct regional read-through beyond U.S. pricing/demand commentary for Eliquis and international access for Vyndaqel.
Supports broader expectations for pharma margin resilience via manufacturing and technology-driven savings through 2029.
Counterpoint
The guidance raise may be more about non-COVID momentum and cost actions than durable demand, while COVID normalization and LOE could still pressure longer-term growth quality.
Key entities
- companyPfizer Inc.
Reported Q2 2026 results and revised full-year revenue guidance, with detailed product line performance and cost-savings plans.
- executiveAlbert Bourla
CEO who emphasized confidence in maintaining the dividend and discussed transformative acquisition opportunities.
- executiveCecile Guegan
Incoming interim CFO who discussed leverage expectations and COVID utilization sensitivity to incidence rates.
- executiveChris Boshoff
Chief Scientific Officer who discussed clinical study analysis plans and Phase III advancement for pipeline assets.
